2.820USD-16.32%Mkt Cap: 134.93M USDP/E: —Last update: 2026-06-01
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the Un…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap134.93M USD
Enterprise Value151.73M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.98M USD
Revenue/Share—
Last Price2.820 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B61.70
EPS (TTM)-0.14
EPS (Forward)—
52W Range
2.0702% of range48.91
52W High48.91 USD
52W Low2.070 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-196.82%
ROA-173.79%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.94M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.13%
Net Debt-3.08M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio3.45
Quick Ratio3.04
Book Value/Sh0.0530 USD
Cash/Share0.0650 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)10.00 USD
Target Range10.00 USD – 10.00 USD
# Analysts1
Ownership
Shares Out.47.34M
Float4.98M
Insiders73.01%
Institutions4.79%
Short Interest
Short Ratio1.2d
Short % Float0.94%
Short % Out.0.38%
Shares Short180.11K
Short (prev mo.)237.71K
Technical
SMA 505.047 (-44.1%)
SMA 2005.604 (-49.7%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)294.04K
Avg Vol (10d)540.46K
Technical Indicators
RSI (14)43.5
MACD-0.6137
MACD Signal-0.6802
MACD Hist.+0.0665
BB Upper4.947 USD
BB Middle3.498 USD
BB Lower2.048 USD
BB Width82.86%
ATR (14)0.7365 USD
Vol Ratio (20d)1.32x